ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 096

Medication Adherence in Adolescents and Young Adults with Childhood Onset SLE

Rotem Semo Oz1, Linda Wagner-Weiner 2, Cuoghi Edens 1, Grace Cameron 1 and Melissa Tesher 1, 1university of chicago, Chicago, 2University of Chicago, Chicago, Illinois

Meeting: 2020 Pediatric Rheumatology Symposium

Keywords: adherence, Compliance, juvenile SLE, medication

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

The 2020 Pediatric Rheumatology Symposium, originally scheduled for April 29 – May 2, was postponed due to COVID-19; therefore, abstracts were not presented as scheduled.

Date: Friday, May 1, 2020

Title: Poster Session 2

Session Type: ACR Abstract Session

Session Time: 5:00PM-6:00PM

Background/Purpose: Compared to adults with SLE, young patients with SLE face particular challenges, including more severe disease, more renal involvement and medications side effects like growth restriction, impaired bone health and delayed puberty. Moreover, patients are asked to adhere to multifaceted, long- term treatments. Poor adherence to medications is a recognized problem among patients with chronic disease and is a well-studied issue in adult patients with SLE. Only a few studies have evaluated medication non-adherence in pediatric SLE. The aim of our study was to evaluate adherence to medications among children and young adults with pediatric onset SLE and identify barriers to adherence.

Methods: Adherence to medications among patients with childhood-onset SLE, aged 12 to 25 years of age, was assessed through 3 evaluation tools: The brief medication questionnaire (BMQ) – Self-report tool for screening adherence and barriers to adherence. The tool includes a 5-item Regimen Screen that asks patients how they took each medication in the past week, a 2-item Belief Screen that asks about drug effects and bothersome features, a 2-item Recall Screen about potential difficulties remembering and 2-item access screen (1). Patients were asked to fill the questionnaire at the time of regular clinic visits.    Lupus medication refill data: Data assessing refills over a 3 months period was collected. A cutoff of less than 80% of the scheduled refills was used for definition of non-adherence   Mycophenolate mofetil (MMF) blood levels, non-adherence defined as mycophenolic acid < 1ug/ml.

Results: Among 23 patients who were enrolled to the study, 52% were found to be non-adherent according to at least 1 evaluation method. Twenty eight percent of patients were found non-adherent according to the BMQ regimen screen and 22% had less than 80% of their lupus medications refilled appropriately.  MMF blood levels was assessed for 13 patients, 38% of them were found to have plasma level < 1 ug/ml. Concordance between the 3 evaluation tools was poor, with only four patients meeting criteria for non-adherence by two or more measures concurrently. Reported barriers to patient adherence included difficulty remembering to take medications (28%), problems paying for medications (29%) and avoidance because of reported adverse effects from the medications (30%).

Conclusion: Non-adherence to medications is highly prevalent among childhood onset lupus patients. Medications adverse effects, cost and difficulty remembering to take medications were found to be common barriers to adherence. Medication adherence should be routinely evaluated among adolescents and young adults with SLE, possibly employing more than one evaluation tool.  The barriers to adherence need to be identified and addressed in order to decrease morbidity and improve patient’s outcome. 

Reference:

(1) Svarstad BL, Chewning BA, Sleath BL, The Brief Medication Questionnaire: a tool for screening patient adherence and barriers to adherence., Claesson C Patient Educ Couns. 1999 Jun;37(2):113-24

Fig I: The the barrier to adherence according to the BMQ questionnaire

Demographic and clinical characteristics


Disclosure: R. Semo Oz, None; L. Wagner-Weiner, None; C. Edens, None; G. Cameron, None; M. Tesher, None.

To cite this abstract in AMA style:

Semo Oz R, Wagner-Weiner L, Edens C, Cameron G, Tesher M. Medication Adherence in Adolescents and Young Adults with Childhood Onset SLE [abstract]. Arthritis Rheumatol. 2020; 72 (suppl 4). https://acrabstracts.org/abstract/medication-adherence-in-adolescents-and-young-adults-with-childhood-onset-sle/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2020 Pediatric Rheumatology Symposium

ACR Meeting Abstracts - https://acrabstracts.org/abstract/medication-adherence-in-adolescents-and-young-adults-with-childhood-onset-sle/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology